...
首页> 外文期刊>Journal of inflammation. >Perfluorochemical (PFC) liquid enhances recombinant adenovirus vector-mediated viral interleukin-10 (AdvIL-10) expression in rodent lung
【24h】

Perfluorochemical (PFC) liquid enhances recombinant adenovirus vector-mediated viral interleukin-10 (AdvIL-10) expression in rodent lung

机译:全氟化物(PFC)液体增强啮齿动物肺中重组腺病毒载体介导的病毒白介素10(AdvIL-10)表达

获取原文
           

摘要

Adenovirus and cationic liposome mediated transfer of Interleukin-10 (IL-10), a potent anti-inflammatory cytokine, has been shown to decrease pro-inflammatory cytokine levels and overall lung inflammation in models of lung transplantation and injury. Limitations to current approaches of IL-10 gene therapy include poor vector delivery methods and pro-inflammatory properties of human IL-10 under certain conditions. We hypothesize that using perfluorochemical (PFC) liquid to deliver the highly homologous viral IL-10 (vIL-10), which is predominantly anti-inflammatory with minimal pro-inflammatory activities, can potentially be a more effective strategy to combat inflammatory lung diseases. In this study, we compare the use of PFC liquid versus aerosolized method to deliver adenovirus encoding the vIL-10 gene (AdvIL-10) in C57Bl6 mice. Detectable vIL-10 levels were measured from bronchoalveolar lavage fluid and lung homogenates at one, four, ten and thirty days after AdvIL-10. Furthermore, we determined if use of PFC liquid could allow for the use of a lower dose of AdvIL-10 by comparing the levels of detectable vIL-10 at different doses of AdvIL-10 delivered +/- PFC liquid. Results showed that PFC liquid enhanced detectable vIL-10 by up to ten fold and that PFC liquid allowed the use of ten-fold less vector. PFC liquid increased detectable vIL-10 in lung homogenates at all time points; however, the increase in detectable vIL-10 in BAL fluid peaked at four days and was no longer evident by thirty days after intratracheal instillation. In summary, this is the first report utilizing PFC liquid to enhance the delivery of a potentially therapeutic molecule, vIL-10. We believe this strategy can be used to perform future studies on the use of the predominantly anti-inflammatory vIL-10 to treat inflammatory lung diseases.
机译:在肺移植和损伤模型中,腺病毒和阳离子脂质体介导的白介素10(IL-10)(一种有效的消炎细胞因子)可降低促炎细胞因子水平和整体肺部炎症。 IL-10基因治疗的当前方法的局限性包括差的载体递送方法和在某些条件下人IL-10的促炎特性。我们假设使用全氟化物(PFC)液体递送高度同源的病毒IL-10(vIL-10)(主要是消炎且促炎活动最少)可能是对抗炎性肺疾病的更有效策略。在这项研究中,我们比较了使用PFC液体和雾化方法在C57B16小鼠中递送编码vIL-10基因(AdvIL-10)的腺病毒。在AdvIL-10后一,四,十和三十天,从支气管肺泡灌洗液和肺匀浆中测量可检测的vIL-10水平。此外,我们通过比较在不同剂量的AdvIL-10输送的+/- PFC液体中可检测的vIL-10的水平,确定了使用PFC液体是否可以允许使用较低剂量的AdvIL-10。结果表明,PFC液体将可检测的vIL-10增强了多达十倍,而PFC液体允许使用的载体减少了十倍。在所有时间点,PFC液体均增加了肺匀浆中可检测的vIL-10。然而,气管内滴注后30天,BAL液中可检测到的vIL-10的增加达到峰值,而到30天时不再明显。总而言之,这是第一个利用PFC液体增强潜在治疗分子vIL-10传递的报告。我们相信,该策略可用于对主要使用消炎性vIL-10治疗炎性肺部疾病进行进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号